New Russian vaccine EnteroMix promises to reduce colon tumors by up to 80% with personalized treatment

Agência Federal Médico-Biológica da Rússia (FMBA) reported a significant advance in oncology treatment with the personalized EnteroMix vaccine. Desenvolvida specifically for colorectal cancer, the new therapy demonstrated a reduction in tumor growth of between 60% and 80%, a result that varies depending on the genetic mutations of each patient.
After three years of research, the scientific documentation for the immunizer was submitted to the Russian Ministério to obtain final approval. The expectation is that, once approved, the vaccine will be made available free of charge to all citizens through the public health system, representing a milestone in accessibility to cutting-edge treatments.
The basis of EnteroMix is its ability to be adapted to each individual. The treatment is formulated based on the genetic analysis of the patient’s tumor, which allows the immune system to recognize and attack malignant cells with high precision, minimizing damage to healthy tissues.
How EnteroMix vaccine technology works
EnteroMix’s scientific approach is based on the use of an oncolytic immunizer, which uses non-pathogenic viral elements. Esses components are designed to specifically penetrate cancer cells, marking them so that the patient’s own immune system can identify and destroy them effectively.
Unlike systemic treatments such as chemotherapy, which indiscriminately affect healthy and diseased cells, this targeted therapy preserves the patient’s vitality. The technology trains the body to fight specific tumor proteins, ensuring a robust immune response focused exclusively on the tumor.
Promising results from early clinical trials
The initial tests of EnteroMix involved the participation of 48 volunteers and presented encouraging results. In 90% of cases, participants demonstrated stabilization of tumor growth, and a significant fraction achieved complete disease regression, according to the researchers.
Veronika Skvortsova, director of the regulatory agency, stated that in certain subtypes of colorectal tumors, the success rate reached 100% during trials. Esse performance is attributed to the vaccine’s precision in activating the body’s defenses against each patient’s specific malignant cells.
In addition to reducing the primary tumor, preliminary studies indicated that the vaccine was able to prevent the development of metastases in the early stages. In animal models, the immune response generated proved to be long-lasting, persisting for more than six months after application.
Planned expansion to other tumor types
Although EnteroMix’s initial focus is colorectal cancer, the technological platform behind the vaccine was designed to be versatile.
FMBA has already started studies to adapt the vaccine to treat glioblastoma, a type of aggressive and difficult to treat brain tumor.
Pre-clinical tests for this application already demonstrate that the vaccine can penetrate the blood-brain barrier, one of the biggest challenges in brain therapies.
Specific formulations for ocular and cutaneous melanomas are also in the validation phase, focusing on common genetic mutations in these types of cancer, which demonstrates the potential for broad application of the technology in various areas of oncology.
Safety and tolerability of the new vaccine
One of EnteroMix’s main differentiators is its high safety profile, confirmed during clinical trials. Menos than 5% of participants reported side effects, which were classified as mild and transient. The most common symptoms included pain at the injection site and low-grade fever, which resolved within 24 hours without the need for medical intervention, a significant contrast to the severe effects of conventional treatments.
This high tolerability is the result of the selection of viral components that do not replicate in healthy human cells and extensive toxicological tests that ensured the absence of cumulative toxicity. The procedure is described by volunteers as simple and comparable to a routine vaccination, with reports of an improvement in quality of life immediately after the first doses, reinforcing the viability of the treatment for a wide audience, including elderly patients or those with comorbidities.
Treatment and access protocol through the public system
The EnteroMix administration protocol is structured to optimize the immune response and ensure long-term efficacy. Treatment begins with a cycle of three initial doses, applied with an interval of four weeks between each one, followed by booster doses every six months or annually, depending on the patient’s risk of recurrence. Todo the process is carried out in an outpatient setting and each session lasts approximately 30 minutes. Antes from the beginning, each patient undergoes a complete genetic evaluation of the tumor, paid for by the state, to allow the manufacture of the personalized formula. Para ensure correct application throughout the country, training programs have already been initiated for more than 10 thousand health professionals. Distribution logistics were planned to cover even the most remote regions of Rússia, using a refrigerated transport network to maintain vaccine stability and ensure universal access to treatment.
The vaccine personalization process
Customizing EnteroMix is a quick and accurate process that begins with a biopsy of the patient’s tumor. The collected material is sent to specialized laboratories, where it undergoes next-generation genetic sequencing to map the unique mutations of cancer cells. Based on this genetic map, a unique vaccine formulation is developed within weeks, ensuring that the treatment is perfectly tailored to combat that specific type of cancer.






